Study of a new injection for dryness and other Sjögren's symptoms
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called JH013 for primary Sjögren's syndrome. It aims to reduce dryness and other symptoms like fatigue and joint pain, and may help people with moderate to severe disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (for the first part of the study) or between 18 and 75 (for the second part)
- You have been diagnosed with primary Sjögren's syndrome according to current classification criteria
- Your Sjögren's symptoms (like dryness, fatigue, or pain) are moderate to severe, as measured by standard questionnaires
- You have certain antibodies in your blood associated with Sjögren's (like anti-SSA or ANA with RF)
- You have some remaining saliva flow (at least a small amount)
- If you could become pregnant, you must have a negative pregnancy test and use reliable contraception
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests whether upadacitinib, a pill that reduces inflammation, can help people with Sjögren's syndrome. It aims to see if the drug can lower disease activity and improve symptoms.
This study tests a low-dose medication called blinatumomab, which targets certain immune cells, to see if it can help control symptoms of moderate to severe Sjögren's syndrome, especially dry eyes. It is for people who have not gotten enough relief from standard treatments.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
Hear when a new Primary Sjögren's Syndrome (pSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.